¼¿ï´ëº´¿ø 2019 À¯Àü¼ººÎÀξϽÉÆ÷Áö¾ö Hereditary Gynecologic Cancer Symposium : 2019-11-30±³À°ÀÏÀÚ : 2019-11-30
±³À°Àå¼Ò : ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç
±³À°ÁÖÁ¦ :
2019 À¯Àü¼ººÎÀξϽÉÆ÷Áö¾ö Hereditary Gynecologic Cancer SymposiumÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044
À̸ÞÀÏ :
gyncancer@gyncancer.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ : 50,000 Àü°øÀÇ : 30,000¿¬±¸¿ø/°£È£»ç : 30,000¸¸ 65¼¼ÀÌ»ó ¹«·á ÁÂÀå,¿¬ÀÚ ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 09:00~09:20 µî·Ï ()
±âŸ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 09:20~09:25 °³È¸»ç ±è½Âö(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå)
±âŸ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 09:25~09:30 ÇÁ·Î±×·¥ ¼Ò°³ ÀÓ¸íö(À¯Àü¼ººÎÀÎ¾Ï ¼ÒÀ§¿øÀå)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 09:30~09:50 Immunogenetics of BRCA-associated breast and ovarian cancers ±è¹Î±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 09:50~10:10 PARP in DNA repair: its therapeutic role ½Å¼ÒÁø(°è¸íÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 10:10~10:30 De cient DNA mismatch repair in Lynch syndrome ÃÖ¹Îö(Â÷ÀÇ´ë)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 10:30~10:40 Q & A ()
ÈÞ½Ä 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 10:40~11:00 Coffee Break ()
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 11:00~11:20 Indonesia Tricia Dewi Anggraeni(Univ. of Indonesia, Indonesia)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 11:20~11:40 Japan Yusuke Kobayashi(Keio Univ., Japan)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 11:40~12:00 China Dongling Zou(Chongqing Univ. Cancer Center, China)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 12:00~12:20 Australia Philip Beale(ANZGOG, Australia)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 12:20~12:30 Q & A ()
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ ½Ãû°¢½Ç 11:00~11:20 Genetic couselling in real world Á¤°í¿î(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ ½Ãû°¢½Ç 11:20~11:40 VUS reclassi cation ÇÏÇüÀÎ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ ½Ãû°¢½Ç 11:40~12:00 Case review1 º¯Á¤¹Ì(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ ½Ãû°¢½Ç 12:00~12:20 Case review2 ÀÌ»êÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ ½Ãû°¢½Ç 12:20~12:30 Q & A ()
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 12:30~13:30 Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer:design, development and place in therapy À¯ÇåÁ¾(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 13:30~13:50 BRCA carrier management: risk of Breast cancer and other cancer ÇÑ»ó¾Æ(°æÈñÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 13:50~14:10 What is different BRCA related BC Non-BRCA related BC À¯Àç¹Î(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 14:10~14:30 Past and future of hereditary breast cancer study in Korea ±è¼º¿ø(´ë¸²¼º¸ðº´¿ø)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 14:30~14:40 Q & A ()
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 14:40~15:00 Genetic risk assessment and BRCA testing for HBOC À̸¶¸®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 15:00~15:20 BRCA de ciency and therapy response ¹éÀ̼±(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 15:20~15:40 Screening for Lynch syndrome in endometrial cancer ±è¹Ì°æ(ÀÌÈÀÇ´ë)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 15:40~15:50 Q & A ()
ÈÞ½Ä 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 15:50~16:10 Coffee Break ()
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 16:10~16:30 Ethical, legal, and social implications (ELSI) of human genomics ÀåÀ±Á¤(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 16:30~16:50 Local integrated system for family counselling ±è¹Ì¼±(Â÷ÀÇ´ë)
±³À°½Ã°£ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 16:50~17:10 Risk-reducing interventions in previvors ³²ÀºÁö(¿¬¼¼ÀÇ´ë)
Åä·Ð 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 17:10~17:20 Q & A ()
±âŸ 11-30 ¼¿ï´ëº´¿ø ÀÇ»ý¸í¿ø±¸¿ø ÁöÇÏ1Ãþ °´ç 17:20~17:25 Æóȸ»ç ()